A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects
NCT ID: NCT03606018
Last Updated: 2018-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
48 participants
INTERVENTIONAL
2017-04-12
2017-07-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Insulin Lispro Mix 25
Single subcutaneous administration of Insulin Lispro Mix 25 in dose 0.4 IU / kg
Insulin Lispro Mix 25
insulin lispro biphasic in doses 0.4 ME/kg
Humalog® Mix 25
Single subcutaneous administration of Humalog® Mix 25 in dose 0.4 IU / kg
Humalog® Mix 25
insulin lispro biphasic in doses 0.4 ME/kg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Insulin Lispro Mix 25
insulin lispro biphasic in doses 0.4 ME/kg
Humalog® Mix 25
insulin lispro biphasic in doses 0.4 ME/kg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Caucasian males having a confirmed healthy diagnosis as per data of standard clinical, laboratory, and instrumental examination methods.
3. Age of 18-50 (both incl.).
4. Body mass index equal to 18.5-27.0 kg/m2.
5. Volunteers' consent to all restrictions imposed during the study, including adequate methods of contraception.
Exclusion Criteria
2. Episodes of hypoglycemia in the anamnesis, or the presence in the family history of cases of a verified diagnosis of diabetes mellitus in the immediate family
3. Fasting plasma glucose\> 6.1 mmol / L
4. HbA1C\> 6%
5. Oral glucose tolerance test - blood glucose level ≥ 7.8 mmol / l (2 hours after loading with glucose)
6. Deep vein thrombosis of lower extremities in a history of life or in a family history.
7. Nicotine dependence (use of tobacco less than 6 months before the start of screening)
8. Taking medications, phytopreparations, biologically active supplements less than 14 days before screening
9. Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information about alcoholism.
10. Donor blood donation in excess of 450 ml, less than 2 months before the study.
11. Participation in a clinical trial of any medications less than 3 months before the start of screening
12. Positive test results for hepatitis C or hepatitis B, HIV, syphilis.
13. Anamnesis information about drug and / or drug dependence and / or substance abuse.
14. Positive test for alcohol content in the exhaled air.
15. A positive test for the content of drugs in the urine.
16. Presence of suspicions of an inflammatory disease of the urinary system as a result of urinalysis.
17. Presence of mental illnesses in the anamnesis.
18. Mental, physical and other reasons that do not allow to adequately assess their behavior and properly fulfill the conditions of the research protocol.
19. Any other conditions that make it difficult, according to the informed opinion of the investigating physician, that volunteer participation in studies
20. Increased sensitivity in the history of heparin, insulin or any of the excipients of the study drugs
21. Weighed allergic anamnesis
22. Abnormalities of the ECG and laboratory parameters from the norms
23. Deviations in basic vital signs: systolic blood pressure is below 100 mm Hg. or above 130 mm Hg, the diastolic blood pressure is below 70 mm Hg. or above 90 mm Hg; heart rate less than 60 or greater than 80
24. Deviations in basic vital signs: systolic blood pressure \<100 mmHg. or\> 130 mm Hg, diastolic blood pressure \<70 mm Hg. Art. or\> 90 mm Hg. Art. heart rate \<60 or\> 80 per minute.
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Geropharm
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
FSBI"ENDOCRINOLOGY NMRC" Ministry of Health of the Russian Federation
Moscow, , Russia
LLL "BioEq"
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LISPRO-25-CL
Identifier Type: -
Identifier Source: org_study_id